[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616208":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Agathe HERB, PharmD","CONTACT","33 3 88 12 75 53","agathe.herb@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100616208","heparins-interference-in-argatroban-measurement-100616208",false,"NCT07302620","HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT","HIMA","Inclusion Criterias:\n\n* Adult patient (≥ 18 years)\n* Patient anticoagulated with UFH or LMWH\n* Sample sent to the Hematology Laboratory of the University Hospitals of Strasbourg (HUS) and analyzed for measurement of the anti-Xa activity of an anticoagulant in routine care\n\nExclusion Criteria:\n\n* Patient receiving an anticoagulant other than UFH or LMWH\n* Insufficient sample volume","ALL","18 Years",{"count":44,"type":45},70,"ESTIMATED","OBSERVATIONAL","Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) provide anticoagulation through their anti-Xa and anti-IIa activity. This anti-IIa activity can lead to an overestimation of argatroban's activity when switching to an anti-IIa anticoagulant such as argatroban. This situation can be critical because argatroban is generally administered following heparin therapy due to suspected heparin-induced thrombocytopenia. Therefore, there is both a significant thrombotic risk induced by the underlying condition and a hemorrhagic risk induced by the anticoagulation. For this reason, it is important to be able to accurately monitor the anti-IIa activity of argatroban. To date, the test used to determine the anti-IIa activity of argatroban at the Hematology Laboratory of the Strasbourg University Hospitals (HUS) is a modified thrombin time (with a calibration curve adapted for argatroban). When switching between several molecules with anti-IIa activity, this test does not allow for the differentiation of the anti-IIa activity attributable to each anticoagulant.\n\nThere are no data in the literature to determine whether heparins interfere with this test, and if so, its extent.",[49],"Thromboembolic Disease",[49,51,52,53,54,55],"HEPARINS","ARGATROBAN","Unfractionated heparin (UFH)","Low molecular weight heparins (LMWH)","Anti-Xa and anti-IIa activity","2025-12-10",{"date":58,"type":59},"2025-12-24","ACTUAL",{"date":61,"type":59},"2024-12-03",{"date":63,"type":45},"2026-01",{"name":5,"class":6},1]